Life sciences organizations are taking inventory of the current state of their ESG programs, and are developing new strategies and roadmaps to create safer products to enhance the patient experience and journey. A strong and well-documented ESG strategy and program is imperative to the future state of the life science industry as a whole.

Please join CohnReznick for a live discussion to better understand the current state of ESG, and hear our take on defining the future state of ESG, in life sciences.